Annovis Bio, Inc. (NYSE: ANVS) priced an underwritten equity offering on April 9 2026, selling 5,263,156 shares of common stock together with an equal number of warrants at a unit price of $1.90. The transaction is expected to generate roughly $10 million in gross proceeds before underwriting discounts and commissions.
The company will use the net proceeds to continue development of its lead Alzheimer’s disease candidate, buntanetap, in Phase 3 studies, and to support general working‑capital needs. Annovis’s cash balance of $19.5 million as of December 31 2025 provides a runway that is expected to extend into the third quarter of 2026, but the new capital raise is intended to secure additional funding for the costly Phase 3 program.
Investors reacted negatively to the announcement, citing the dilutive nature of the offering. The market’s concern over dilution reflects the immediate impact on shareholder ownership, even as the company’s long‑term strategy focuses on advancing buntanetap.
Prior to this offering, Annovis had raised $7.5 million in November 2023 and $21 million in February 2025 to support earlier phases of its clinical program. The company’s CFO departed on March 23 2026, and a U.S. patent covering buntanetap’s use in neurological injury was issued on April 2 2026. Annovis also announced a partnership with NeuroRPM to monitor Parkinson’s disease studies and published a historical review of buntanetap in The Scientist.
Each warrant is exercisable for one share of common stock at $2.50 per share, becomes exercisable six months after issuance, and expires five years and six months after the issue date. The offering is underwritten by Canaccord Genuity and is being made pursuant to a shelf registration statement on Form S‑3 (Registration No. 333‑276814) that was filed with the SEC on February 1 2024 and declared effective on February 12 2024.
revised_sentiment_rating":0} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.